EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy

Asier Lizama-Muñoz iD, Julio Plaza-Diaz iD

Biomolecules · 29.04.2025 · 15 (5) · 639

DOI: 10.3390/biom15050639 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 29.04.2025. Verfasst von Asier Lizama-Muñoz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology and Immunology III, Faculty of Medicine, University of Granada, 18016 Granada, Spain. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Extracellular Vesicles, Neoplasms, Single-Domain Antibodies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains one of the leading causes of mortality worldwide, with a growing need for precise and effective treatments. Traditional therapies such as chemotherapy and radiotherapy have limitations, including off-target effects and drug resistance. In recent years, targeted therapies have emerged as promising alternatives, aiming to improve treatment specificity and reduce systemic toxicity. Among the most innovative approaches, bispecific antibodies, nanobodies, and extracellular vesicles offer distinct and complementary mechanisms for cancer therapy. Bispecific antibodies enhance immune responses and enable dual-targeting of cancer cells, nanobodies provide superior tumor penetration due to their small size, and extracellular vesicles present a novel platform for drug and RNA delivery. This work aims to review and analyze these three approaches, assessing their current applications, advantages, challenges, and future perspectives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificExtracellular VesiclesNeoplasmsSingle-Domain AntibodiesHumansAnimalsDrug Delivery SystemsMolecular Targeted Therapy

Stichwörter der Autor:innen

bispecific antibodiescancer therapyextracellular vesiclesnanobodiestarget therapy

Substanzen

Antibodies, BispecificSingle-Domain Antibodies

Autor:innen und Institutionen

  • Department of Biochemistry, Molecular Biology and Immunology III, Faculty of Medicine, University of Granada, 18016 Granada, Spain.
  • Clinical Analysis and Immunology Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
  • ANUT-DSM (Alimentaciò, Nutrició Desenvolupament i Salut Mental), Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43201 Reus, Spain.
  • School of Health Sciences, Universidad Internacional de La Rioja, Avenida de la Paz 137, 26006 Logroño, Spain.

ORCID-Profile: Asier Lizama-Muñoz, Julio Plaza-Diaz

Zitieren

APA

Lizama-Muñoz, A., & Plaza-Diaz, J. (2025). Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy. Biomolecules, 15(5), 639. https://doi.org/10.3390/biom15050639

Vancouver

Lizama-Muñoz A, Plaza-Diaz J. Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy. Biomolecules. 2025;15(5):639. doi:10.3390/biom15050639

BibTeX
@article{LizamaMuoz2025,
  author = {Lizama-Muñoz, Asier and Plaza-Diaz, Julio},
  title = {Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {5},
  pages = {639},
  doi = {10.3390/biom15050639}
}
Kostenlos starten →